Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: A post hoc subgroup analysis of a double-blind, randomized controlled trial

Canadian Journal of Psychiatry

Volumn 58, Issue 7, 2013, Pages 402-408

  Amminger, G Paul ^a,b   Chanen, Andrew M ^b,c   Ohmann, Susanne ^a   Klier, Claudia M ^d   Mossaheb, Nilufar ^a   Bechdolf, Andreas ^e   Nelson, Barnaby ^b,c   Thompson, Andrew ^b,c   McGorry, Patrick D ^b,c   Yung, Alison R ^c   Schäfer, Miriam R ^a,b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^d UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Adolescents; Borderline personality disorder; Omega 3 fatty acids; Randomized controlled trial; Ultra high risk

Indexed keywords

OMEGA 3 FATTY ACID;

ADOLESCENT; ARTICLE; BORDERLINE STATE; CLINICAL TRIAL; ERYTHROCYTE; FEMALE; HUMAN; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOCIAL PSYCHOLOGY; SUPPLEMENTATION; UNSPECIFIED SIDE EFFECT;

EID: 84879909005     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371305800705     Document Type: Article

References (41)

1. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): APA; 1994.
2. Trull TJ, Jahng S, Tomko RL, et al. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord. 2010;24(4):412-426.
3. Zimmerman M, Chelminski I, Young D. The frequency of personality disorders in psychiatric patients. Psychiatr Clin North Am. 2008;31(3):405-420. (Pubitemid 351970130)
4. Tackett JL, Balsis S, Oltmanns TF, et al. A unifying perspective on personality pathology across the life span: developmental considerations for the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders. Dev Psychopathol. 2009;21(3):687-713.
5. Johnson JG, Cohen P, Kasen S, et al. Age-related change in personality disorder trait levels between early adolescence and adulthood: a community-based longitudinal investigation. Acta Psychiatr Scand. 2000;102(4):265-275.
6. Samuels J, Eaton WW, Bienvenu O, et al. Prevalence and correlates of personality disorders in a community sample. Br J Psychiatry. 2002;180(6):536-542. (Pubitemid 34596805)
7. Ullrich S, Coid J. The age distribution of self-reported personality disorder traits in a household population. J Pers Disord. 2009;23(2):187-200.
8. Chanen AM, Jovev M, McCutcheon L, et al. Borderline personality disorder in young people and the prospects for prevention and early intervention. Curr Psychiatry Rev. 2008;4(1):48-57. (Pubitemid 351513497)
9. Miller AL, Muehlenkamp JJ, Jacobson CM. Fact or fiction: diagnosing borderline personality disorder in adolescents. Clin Psychol Rev. 2008;28(6):969-981.
10. Skodol AE. Scientific issues in the revision of personality disorders for DSM-5. Pers Ment Health. 2011;5(2):97-111.
11. Gunderson JG, Stout RL, McGlashan TH, et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Arch Gen Psychiatry. 2011;68(8):827-837.
12. Leichsenring F, Leibing E, Kruse J, et al. Borderline personality disorder. Lancet. 2011;377(9759):74-84.
13. Chanen AM, Jackson HJ, McCutcheon LK, et al. Early intervention for adolescents with borderline personality disorder using cognitive analytic therapy: randomised controlled trial. Br J Psychiatry. 2008;193(6):477-484.
14. Lieb K, Vollm B, Rucker G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomized trials. Br J Psychiatry. 2010;196:4-12.
15. Tsapakis EM, Soldani F, Tondo L, et al. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry. 2010;193:10-17. (Pubitemid 351946803)
16. Ingenhoven TJM, Duivenvoorden HJ. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol. 2011;31(4):489-496.
17. Paris J. Pharmacological treatments for personality disorders. Int Rev Psychiatry. 2011;23(3):303-309.
18. Gesch CB, Hammond SM, Hampson SE, et al. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomized, placebo-controlled trial. Br J Psychiatry. 2002;181:22-28. (Pubitemid 34717834)
19. Garland MR, Hallahan B, McNamara M, et al. Lipids and essential fatty acids in patients presenting with self-harm. Br J Psychiatry. 2007;190:112-117.
20. Hallahan B, Hibbeln JR, Davis JM, et al. Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry. 2007;190:118-122.
21. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160:167-169. (Pubitemid 36042442)
22. Barnow S, Arens EA, Sieswerda S, et al. Borderline personality disorder and psychosis: a review. Curr Psychiatry Rep. 2010;12(3):186-195.
23. Glaser JP, Van Os J, Thewissen V, et al. Psychotic reactivity in borderline personality disorder. Acta Psychiatr Scand. 2010;121(2):125-134.
24. Slotema CW, Daalman K, Blom JD, et al. Auditory verbal hallucinations in patients with borderline personality disorder are similar to those in schizophrenia. Psychol Med. 2012;16:1-6.
25. George A, Soloff PH. Schizotypal symptoms in patients with borderline personality disorders. Am J Psychiatry. 1986;143(2):212-215. (Pubitemid 16114366)
26. Thompson A, Nelson B, Domingues I, et al. Borderline personality features and transition to psychosis in an "ultra high risk" (UHR) population: a case-control study. Early Interv Psychiatry. 2012;6(3):247-255.
27. Francey SM, Jovev M, Phassouliotis C, et al. Co-morbid borderline personality disorder and first episode psychosis: how many and what happens? [Meeting abstract]. Schizophr Res. 2006;86:S113-S113.
28. Gleeson JFM, Chanen AM, Cotton SM, et al. Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Interv Psychiatry. 2012;6(1):21-29.
29. Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146-154.
30. Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl. 1998;172:14-20. (Pubitemid 28258893)
31. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
32. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004;185:291-297. (Pubitemid 39331330)
33. Andreasen NC, Endicott J, Spitzer RL, et al. The family history method using diagnostic criteria. Reliability and validity. Arch Gen Psychiatry. 1977;34(10):1229-1235. (Pubitemid 8216736)
34. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
35. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. Acta Psychiatr Scand. 1987;334:1-100.
36. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67:1954-1967. (Pubitemid 46048194)
37. Goodman M, New AS, Triebwasser J, et al. Phenotype, endophenotype, and genotype comparisons between borderline personality disorder and major depressive disorder. J Pers Disord. 2010;24(1):38-59.
38. Sublette ME, Russ MJ, Smith GS. Evidence for a role of the arachidonic acid cascade in affective disorders: a review. Bipolar Disord. 2010;6:95-105.
39. Zanarini MC, Stanley B, Black DW, et al. Methodological considerations for treatment trials for persons with borderline personality disorder. Ann Clin Psychiatry. 2010;22(2):75-83.
40. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010;91:757-770.
41. Sublette ME, Ellis SP, Geant AL, et al. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72(12):1577-1584.